KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Cash from Operations: 2016-2024

Historic Cash from Operations for Moderna (MRNA) over the last 9 years, with Dec 2024 value amounting to -$3.0 billion.

  • Moderna's Cash from Operations rose 45.91% to -$847.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.0 billion, marking a year-over-year increase of 38.32%. This contributed to the annual value of -$3.0 billion for FY2024, which is 3.66% up from last year.
  • Moderna's Cash from Operations amounted to -$3.0 billion in FY2024, which was up 3.66% from -$3.1 billion recorded in FY2023.
  • Over the past 5 years, Moderna's Cash from Operations peaked at $13.6 billion during FY2021, and registered a low of -$3.1 billion during FY2023.
  • Over the past 3 years, Moderna's median Cash from Operations value was -$3.0 billion (recorded in 2024), while the average stood at -$380.3 million.
  • As far as peak fluctuations go, Moderna's Cash from Operations surged by 571.93% in 2021, and later slumped by 162.60% in 2023.
  • Over the past 5 years, Moderna's Cash from Operations (Yearly) stood at $2.0 billion in 2020, then skyrocketed by 571.93% to $13.6 billion in 2021, then crashed by 63.43% to $5.0 billion in 2022, then crashed by 162.60% to -$3.1 billion in 2023, then increased by 3.66% to -$3.0 billion in 2024.